英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字,中文词皆可:

Slower    音标拼音: [sl'oɚ]
较慢的

较慢的

slower
adv 1: more slowly

Slow \Slow\ (sl[=o]), a. [Compar. {Slower} (sl[=o]"[~e]r);
superl. {Slowest}.] [OE. slow, slaw, AS. sl[=a]w; akin to OS.
sl[=e]u blunt, dull, D. sleeuw, slee, sour, OHG. sl[=e]o
blunt, dull, Icel. sl[=o]r, sl[ae]r, Dan. sl["o]v, Sw.
sl["o]. Cf. {Sloe}, and {Sloth}.]
1. Moving a short space in a relatively long time; not swift;
not quick in motion; not rapid; moderate; deliberate; as,
a slow stream; a slow motion.
[1913 Webster]

2. Not happening in a short time; gradual; late.
[1913 Webster]

These changes in the heavens, though slow, produced
Like change on sea and land, sidereal blast.
--Milton.
[1913 Webster]

3. Not ready; not prompt or quick; dilatory; sluggish; as,
slow of speech, and slow of tongue.
[1913 Webster]

Fixed on defense, the Trojans are not slow
To guard their shore from an expected foe. --Dryden.
[1913 Webster]

4. Not hasty; not precipitate; acting with deliberation;
tardy; inactive.
[1913 Webster]

He that is slow to wrath is of great understanding.
--Prov. xiv.
29.
[1913 Webster]

5. Behind in time; indicating a time earlier than the true
time; as, the clock or watch is slow.
[1913 Webster]

6. Not advancing or improving rapidly; as, the slow growth of
arts and sciences.
[1913 Webster]

7. Heavy in wit; not alert, prompt, or spirited; wearisome;
dull. [Colloq.] --Dickens. Thackeray.
[1913 Webster]

Note: Slow is often used in the formation of compounds for
the most part self-explaining; as, slow-gaited,
slow-paced, slow-sighted, slow-winged, and the like.
[1913 Webster]

{Slow coach}, a slow person. See def.7, above. [Colloq.]

{Slow lemur}, or {Slow loris} (Zool.), an East Indian
nocturnal lemurine animal ({Nycticebus tardigradus}) about
the size of a small cat; -- so called from its slow and
deliberate movements. It has very large round eyes and is
without a tail. Called also {bashful Billy}.

{Slow match}. See under {Match}.
[1913 Webster]

Syn: Dilatory; late; lingering; tardy; sluggish; dull;
inactive.

Usage: {Slow}, {Tardy}, {Dilatory}. Slow is the wider term,
denoting either a want of rapid motion or inertness of
intellect. Dilatory signifies a proneness to defer, a
habit of delaying the performance of what we know must
be done. Tardy denotes the habit of being behind hand;
as, tardy in making up one's acounts.
[1913 Webster]



安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Bempedoic Acid and Cardiovascular Outcomes in Statin . . .
    The risk of death from cardiovascular causes, nonfatal stroke, or nonfatal myocardial infarction (the first key secondary end point) was 15% lower with bempedoic acid than with placebo, and the
  • U. S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET . . .
    U S FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
  • Nexletol shows CLEAR benefit in cardiovascular outcome trial
    New data for Esperion’s cholesterol lowering daily pill Nexletol, used when statins are not working in people at risk of a heart attack, could inject some momentum into the drug’s slow rollout
  • Evaluation of Major Cardiovascular Events in Participants . . .
    The purpose of this study is to determine if treatment with bempedoic acid (ETC-1002) versus placebo decreases the risk of cardiovascular events in participants who have or are at high risk for cardiovascular disease and are statin intolerant
  • U. S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET . . .
    ANN ARBOR, Mich , March 22, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL ® (bempedoic acid) Tablets and NEXLIZET ® (bempedoic acid and ezetimibe) Tablets based on positive CLEAR Outcomes data that include indications for cardiovascular risk reduction and expanded
  • Esperion Showcases New Data from CLEAR Outcomes Highlighting . . .
    In the cardiovascular outcomes trial, the rates were 1 2% for bempedoic acid and 0 9% for placebo Discontinue NEXLIZET or NEXLETOL at the first sign of tendon rupture
  • U. S. FDA Approves Broad New Labels for Esperion’s NEXLETOL . . .
    Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL ® (bempedoic acid) Tablets and NEXLIZET ® (bempedoic acid and ezetimibe) Tablets based on positive CLEAR Outcomes data that include indications for cardiovascular risk reduction and expanded LDL-C lowering in both primary and secondary
  • Impact of SGLT2 Inhibitors on Mortality Across Different . . .
    SGLT2 inhibitors as a class provide a consistent and significant reduction in all-cause mortality across both short-term (up to one year) and long-term follow-up, while the long-term benefit extends to chronic heart failure, CKD, and high-risk DM Sodium-glucose cotransporter-2 (SGLT2) inhibitors offer glucose-lowering, cardio-protective and reno-protective properties Mortality rates
  • Bempedoic Acid, the First-in-Class Oral ATP Citrate Lyase . . .
    Bempedoic acid is a new drug that improves the control of cholesterol levels, either as monotherapy or in combination with existing lipid-lowering therapies, and shows clinical efficacy in cardiovascular disease patients Thus, patients with
  • FDA Expands Labels for Nexletol, Nexlizet to Prevent Heart . . .
    U S FDA approves broad new labels for Nexletol and Nexlizet to prevent heart attacks and cardiovascular procedures in both primary and secondary prevention patients, regardless of statin use





中文字典-英文字典  2005-2009